- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04709172
Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in December 2019, and has since spread worldwide. The disease is mild in 85% of cases but the remaining 15% requires hospitalization and/or intensive care.
Recent publications show that a significant number of COVID-19 patients are co-infected with one or more pathogens. Most co-infections occurred within 1-4 days of onset of COVID-19 disease and a considerable number of patients arrive to the Emergency rooms with mild-moderate respiratory symptoms compatible with pneumonia of presumed bacterial origin and not severe enough for requiring hospitalization. It therefore seems reasonable to adopt therapeutic strategies for these patients that are effective and easy to follow in the outpatient setting.
Cefditoren (CDN) is a third-generation cephalosporin for oral administration. CDN has a broad spectrum of activity and is particularly active against the bacterial pathogens involved in community respiratory tract infections. Besides that, the use of CDN has been associated with a marked decrease in circulating levels of IL-6 and other pro-inflammatory cytokines and mediators of epithelial damage. The aim of this study is to demonstrate that CDN improves clinical condition in patients with mild-moderate COVID-19 and symptoms of bacterial pneumonia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in December 2019, and has since spread worldwide. The novel coronavirus is now referred to as severe and critical acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease is mild in 85% of cases but the remaining 15% requires hospitalization and/or intensive care.
Recent publications show that a variable number of COVID-19 patients are co-infected with one or more pathogens. Most co-infections occurred within 1-4 days of onset of COVID-19 disease and in a retrospective study, secondary infection was observed in 50% of non-survivor patients.
In COVID-19 patients the elevated inflammatory cytokines and other inflammatory mediators present suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of this disease. The elevated cytokine levels, specifically IL-6, may also be responsible for the lethal complications of COVID-19. Therefore, the interleukin-6 (IL-6) blockade has been proposed as one of the strategies to manage COVID-19-induced CRS.
A considerable number of COVID-19 patients arrive to the Emergency rooms with mild-moderate respiratory symptoms compatible with pneumonia of presumed bacterial origin not severe enough for requiring hospitalization. It therefore seems reasonable to adopt therapeutic strategies for these patients that are effective and easy to follow in the outpatient setting to avoid overloading the Health System.
Cefditoren (CDN) is a third-generation cephalosporin for oral administration. CDN has a broad spectrum of activity and is particularly active against the bacterial pathogens involved in community respiratory tract infections. The results of clinical trials with CDN on community-acquired pneumonia showed percentages of clinical and microbiological efficacy around 85%. On the other hand, the use of CDN has been associated with a marked decrease in circulating levels of IL-6 and other pro-inflammatory cytokines and mediators of epithelial damage such as Krebs von den Lungen-6 (KL-6).
Considering the above and the current estate of knowledge against SARS-CoV-2, we have considered of relevance to study the efficacy of CDN in a series of patients with mild-moderate COVID-19 and with symptoms compatible with pneumonia of presumed bacterial origin, seen at the Emergency room of a public hospital and followed on outpatient basis.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Madrid
-
Coslada, Madrid, Spain, 28822
- HU Henares
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult ≥18 years
- Positive for SARS CoV-2
- Radiological and clinical signs of mild-moderate pneumonia
- Fever ≥37.7 ºC
- Sat O2> 94% and respiratory rate <24 on admission
- Able of taking oral medication
- HIV negative
- Written and signed consent
Exclusion Criteria:
- Concomitant treatments with drugs of demonstrated or potential action against SARS CoV-2 within the previous 24 hours.
- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 5 times the upper limit
- corrected QT (QTc) interval prolongation> 450 msg,
- Moderate or severe renal impairment (creatinine<50ml/min)
- Severe hepatic impairment (Child-Pugh C)
- Pregnancy or childbearing
- Allergy to penicillin or any other beta-lactam
- Primary carnitine deficiency
- Malabsorption or swallowing problems
- Inability to understand and follow study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cefditoren pivoxil 400mg
Cefditoren pivoxil 400mg bid for 7 days
|
Cefditoren pivoxil 400mg bid for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of patient status
Time Frame: 28 days
|
Evolution of the status of the patient defined by the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19.
This is a 0-8 score where higher scores mean a better or worse outcome.
|
28 days
|
Assessment of Clinical improvement
Time Frame: 28 days
|
Evaluation of clinical condition through a Clinical Improvement questionnaire.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional visit to the Emergency room
Time Frame: 28 days
|
New attendance to the hospital due to worsening
|
28 days
|
Need for hospitalization
Time Frame: 28 days
|
Hospitalization due to worsening
|
28 days
|
Occurrence of adverse events
Time Frame: 28 days
|
Adverse reactions
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cristóbal Rodríguez Leal, Dr, HU Henares
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MPS-ME1207/401
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly
Clinical Trials on Cefditoren pivoxil 400mg
-
Thammasat UniversityUnknownRhinosinusitisThailand
-
Tedec-Meiji Farma, S.A.CompletedUrinary Tract InfectionsSpain, Greece
-
Hartford HospitalSpero TherapeuticsCompletedDiabetes | ABSSSI | Healthy Volunteers | Wound InfectionUnited States
-
Spero TherapeuticsCelerionCompleted
-
Spero TherapeuticsCompletedHealthy VolunteersUnited States
-
SK Chemicals Co., Ltd.TerminatedAsthmaKorea, Republic of
-
Spero TherapeuticsCompleted
-
CTI BioPharmaSGS S.A.CompletedMyelofibrosisMoldova, Republic of, Germany
-
Dream PlusCompletedAndrogenic AlopeciaKorea, Republic of
-
University of ChicagoUnknown